Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 9/20 | 0.49 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.39 |
| ▸ | CTSA | P10619 | 6/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5425106 | 0.84 | CRHR1 (0.51) | CRHR1RUNX1CTSASCN9A | |
| SCHEMBL5409101 | 0.82 | CRHR1 (0.48) | CRHR1RUNX1CTSASCN9AALPL | |
| SCHEMBL14416669 | 0.82 | CRHR1 (0.52) | CRHR1CTSASCN9A | |
| SCHEMBL5439627 | 0.80 | CRHR1 (0.56) | CRHR1RUNX1CTSASCN9A | |
| SCHEMBL5539444 | 0.79 | CRHR1 (0.54) | CRHR1SCN9A | |
| SCHEMBL6203375 | 0.77 | CRHR1 (0.45) | CRHR1RUNX1CTSASCN9A | |
| SCHEMBL5404686 | 0.76 | PIM1 (0.46) | CRHR1RUNX1SCN9A | |
| SCHEMBL5420376 | 0.73 | CRHR1 (0.43) | CRHR1RUNX1SCN9A | |
| SCHEMBL4883920 | 0.72 | CRHR1 (0.60) | CRHR1CTSASCN9A | |
| SCHEMBL4885196 | 0.72 | CRHR1 (0.60) | CRHR1RUNX1SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225287-A1 | Substituted Arylpyrazines | YOON TAEYOUNG | 2007-09-27 | — | — | US | disclosed |
| US-20070225287-A1 | Substituted Arylpyrazines | YOON TAEYOUNG | 2007-09-27 | — | — | US | disclosed |
| US-7202250-B2 | Substituted arylpyrazines | NEUROGEN CORPORATION (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202250-B2 | Substituted arylpyrazines | NEUROGEN CORPORATION (US) | 2007-04-10 | — | — | US | disclosed |
| US-20070043056-A1 | 5-Substituted-2-arylpyrazines | NEUROGEN CORPORATION (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070043056-A1 | 5-Substituted-2-arylpyrazines | NEUROGEN CORPORATION (US) | 2007-02-22 | — | — | US | disclosed |
| US-7179807-B2 | 5-substituted-2-arylpyrazines | NEUROGEN CORPORATION (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179807-B2 | 5-substituted-2-arylpyrazines | NEUROGEN CORPORATION (US) | 2007-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225287-A1 | Substituted Arylpyrazines | CRHR1, CRHR2, CRH | CRHR1 1/4885RUNX1 979/4885CTSA 1574/4885 |
| US-20070043056-A1 | 5-Substituted-2-arylpyrazines | HTR5A, CRHR2, HTR2C | CRHR1 5/4885RUNX1 2039/4885CTSA 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.